Vicent M. Guillem

Vicent M. Guillem

Auto-generated profile, based on publicly available information

Vicent M. Guillem

Servicio de Hematología y Oncología, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2001 in Journal of Controlled Release
Verified
Journal Article
Closed access
IMInés Moret
Inés Moret
JPJosé Esteban Peris
José Esteban Peris
VGVicent M. Guillem
Vicent M. Guillem
MBMarta Benet
Marta Benet
FRFernando Revert
Fernando Revert
Salvador F AliñoSalvador F Aliño
Salvador F Aliño

1 August 2011 in Leukemia Research
Verified
Journal Article
Closed access
MMMargherita Maffioli
Margherita Maffioli
MCMireia Camós
Mireia Camós
AGAnna Gaya
Anna Gaya
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
AÁAlberto Álvarez-Larrán
Alberto Álvarez-Larrán
FCFrancisco Cervantes
Francisco Cervantes

3 May 2007 in Leukemia
Verified
Journal Article
Closed access
VGV M Guillem
V M Guillem
MCM Collado
M Collado
MTM J Terol
M J Terol
MCMaria José Calasanz
Maria José Calasanz
JEJ Esteve
J Esteve
MDMar Tormo Diaz
Mar Tormo Diaz

1 January 2008 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
VGVicent Guillem
Vicent Guillem
MDMar Tormo Diaz
Mar Tormo Diaz
Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) are malignancies occurring after exposure to chemotherapy and/or radiotherapy. Several studies have addressed cumulative dose, dose intensity and exposure to specific agents of preceding cytotoxic therapy in relation to the risk of developing such leukemia. Since only a small percentage of patients exposed to cytotoxic therapy develop t-MDS/AML, it has been suggested that some genetic predisposition may be involved, specifically associated to polymorphisms in certain genes involved in chemotherapy/radiotherapy response - fundamentally genes intervening in drug detoxification and DNA synthesis and repair. A review is made of the genetic studies related to t-MDS/AML predisposition, focusing on the mechanistic findings of how specific chemotherapeutic drug exposure produces DNA damage and induces the chromosomal abnormalities characteristic of t-MDS/AML, the molecular pathways involved in repairing such drug induced damage, and the way in which they influence t-MDS/AML genesis. Specific issues are (a) the interaction of topoisomerase II inhibitors, alkylators and antimetabolite drugs with DNA repair mechanisms and their impact on t-MDS/AML leukemogenicity and (b) the influence of DNA polymorphisms in genes involved in DNA repair, drug metabolization and nucleotide synthesis, paying special attention to the relevance of folate metabolism. Finally, we discuss some aspects relating to study design that are most suitable for characterizing associations between drug exposure and genotypes related to t-MDS/AML risk - stressing the importance of the inclusion of chemotherapy-exposed control groups.

31 May 2012 in Blood
Verified
Journal Article
Closed access
PDF file
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
APArturo Pereira
Arturo Pereira
FCFrancisco Cervantes
Francisco Cervantes
ALAlberto Alvarez Larran
Alberto Alvarez Larran
MCMaría Collado
María Collado
VGVicent Guillem
Vicent Guillem
Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have an increased incidence of acute myeloid leukemia and new nonhematologic malignancies compared with the general population. However, information on the factors determining the risk for such complications is limited. In the present study, we investigated whether constitutional genetic variations in DNA repair predispose to leukemic transformation and new nonmyeloid neoplasias in patients with ET and PV. Case-control studies for predisposition to both types of malignancies were nested in a cohort of 422 subjects diagnosed with ET or PV during the period 1973-2010 in several institutions in Spain. A total of 64 incidence cases of leukemia and 50 cases of primary nonmyeloid cancers were accrued. At conditional regression analysis, the Gln/Gln genotype in the XPD codon 751 showed the strongest association with both leukemic transformation (odds ratio [OR] = 4.9; 95% confidence interval [95% CI], 2.0-12) and development of nonmyeloid malignancies (OR = 4.2; 95% CI, 1.5-12). Additional predictive factors were exposure to cytoreductive agents for leukemic transformation (OR = 3.5; 95% CI, 2.0-6.2) and age for nonmyeloid malignancies (OR = 2.0; 95% CI, 1.4-2.8). These findings provide further evidence about the contribution of inherited genetic variations to the pathogenesis and clinical course of myeloproliferative neoplasms.

23 June 2010 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
VGVicent M. Guillem
Vicent M. Guillem
FCFrancisco Cervantes
Francisco Cervantes
JMJesús Martínez
Jesús Martínez
ALAlberto Alvarez Larran
Alberto Alvarez Larran
MCMaría Collado
María Collado
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
Chronic myeloid leukemia (CML) is driven by the BCR‐ABL protein, which promotes the proliferation and viability of the leukemic cells. Moreover, BCR‐ABL induces genomic instability that can contribute to the emergence of resistant clones to the ABL kinase inhibitors. It is currently unknown whether the inherited individual capability to repair DNA damage could affect the treatment results. To address this, a comprehensive analysis of single nucleotide polimorfisms (SNPs) on the nucleotide excision repair (NER) genes (ERCC2‐ERCC8, RPA1‐RPA3, LIG1, RAD23B, XPA, XPC) was performed in 92 chronic phase CML patients treated with imatinib upfront. ERCC5 and XPC SNPs correlated with the response to imatinib. Haplotype analysis of XPC showed that the wild‐type haplotype (499C‐939A) was associated with a better response to imatinib. Moreover, the 5‐year failure free survival for CA carriers was significantly better than that of the non‐CA carriers (98% vs. 73%; P = 0.02). In the multivariate logistic model with genetic data and clinical covariates, the hemoglobin (Hb) level and the XPC haplotype were independently associated with the treatment response, with patients having a Hb ≤11 g/dl (Odds ratio [OR] = 5.0, 95% confidence interval [CI] = 1.5–16.1) or a non‐CA XPC haplotype (OR = 4.1, 95% CI = 1.6–10.6) being at higher risk of suboptimal response/treatment failure. Our findings suggest that genetic polymorphisms in the NER pathway may influence the results to imatinib treatment in CML. Am. J. Hematol., 2010.